TY - JOUR
T1 - Contemporary Epidemiology of Chronic Liver Disease and Cirrhosis
AU - Moon, Andrew M.
AU - Singal, Amit G.
AU - Tapper, Elliot B.
N1 - Funding Information:
Funding This research was supported in part by National Institutes of Health grant T32 DK007634 (A.M.). Dr. Singal's research is supported by National Institutes of Health grantsU01CA230694 and R01MD12565. Also supported by the National Institutes of Health through the Michigan Institute for Clinical and Health Research (KL2TR002241 to E.T.). The content is solely the responsibility of the authors and does not necessarily represent the official views of the National Institutes of Health. Conflicts of interest These authors disclose the following: Amit Singal has received grant funding from AbbVie and has served on advisory boards for Gilead and AbbVie; and Elliot Tapper has received grant funding (to the University of Michigan) from Gilead and Valeant, consulted for Novartis and Allergan, and has served on advisory boards for Salix/Bausch and Mallinckrodt. The remaining author discloses no conflicts.
Funding Information:
Funding This research was supported in part by National Institutes of Health grant T32 DK007634 (A.M.). Dr. Singal’s research is supported by National Institutes of Health grants U01CA230694 and R01MD12565 . Also supported by the National Institutes of Health through the Michigan Institute for Clinical and Health Research ( KL2TR002241 to E.T.). The content is solely the responsibility of the authors and does not necessarily represent the official views of the National Institutes of Health.
Publisher Copyright:
© 2020 AGA Institute
PY - 2020/11
Y1 - 2020/11
N2 - Background & Aims: Accurate estimates for the contemporary burden of chronic liver disease (CLD) are vital for setting clinical, research, and policy priorities. We aimed to review the incidence, prevalence, and mortality of CLD and its resulting complications, including cirrhosis and hepatocellular carcinoma (HCC). Methods: We reviewed the published literature on the incidence, prevalence, trends of various etiologies of CLD and its resulting complications. In addition, we provided updated data from the Centers for Disease Control and Global Burden of Disease Study on the morbidity and mortality of CLD, cirrhosis, and hepatocellular carcinoma (HCC). Lastly, we assessed the strengths and weaknesses of available sources of data in hopes of providing important context to these national estimates of cirrhosis burden. Results: An estimated 1.5 billion persons have CLD worldwide and the age-standardized incidence of CLD and cirrhosis is 20.7/100,000, a 13% increase since 2000. Similarly, cirrhosis prevalence and mortality has increased in recent years in the United States. The epidemiology of CLD is shifting, reflecting implementation of large-scale hepatitis B vaccination and hepatitis C treatment programs, the increasing prevalence of the metabolic syndrome, and increasing alcohol misuse. Conclusions: The global burden of CLD and cirrhosis is substantial. Although vaccination, screening, and antiviral treatment campaigns for hepatitis B and C have reduced the CLD burden in some parts of the world, concomitant increases in injection drug use, alcohol misuse, and metabolic syndrome threaten these trends. Ongoing efforts to address CLD-related morbidity and mortality require accurate contemporary estimates of epidemiology and outcomes.
AB - Background & Aims: Accurate estimates for the contemporary burden of chronic liver disease (CLD) are vital for setting clinical, research, and policy priorities. We aimed to review the incidence, prevalence, and mortality of CLD and its resulting complications, including cirrhosis and hepatocellular carcinoma (HCC). Methods: We reviewed the published literature on the incidence, prevalence, trends of various etiologies of CLD and its resulting complications. In addition, we provided updated data from the Centers for Disease Control and Global Burden of Disease Study on the morbidity and mortality of CLD, cirrhosis, and hepatocellular carcinoma (HCC). Lastly, we assessed the strengths and weaknesses of available sources of data in hopes of providing important context to these national estimates of cirrhosis burden. Results: An estimated 1.5 billion persons have CLD worldwide and the age-standardized incidence of CLD and cirrhosis is 20.7/100,000, a 13% increase since 2000. Similarly, cirrhosis prevalence and mortality has increased in recent years in the United States. The epidemiology of CLD is shifting, reflecting implementation of large-scale hepatitis B vaccination and hepatitis C treatment programs, the increasing prevalence of the metabolic syndrome, and increasing alcohol misuse. Conclusions: The global burden of CLD and cirrhosis is substantial. Although vaccination, screening, and antiviral treatment campaigns for hepatitis B and C have reduced the CLD burden in some parts of the world, concomitant increases in injection drug use, alcohol misuse, and metabolic syndrome threaten these trends. Ongoing efforts to address CLD-related morbidity and mortality require accurate contemporary estimates of epidemiology and outcomes.
KW - Alcohol-related
KW - Hepatitis B
KW - Hepatitis C
KW - Liver Cancer
KW - Nonalcoholic Fatty Liver Disease
UR - http://www.scopus.com/inward/record.url?scp=85091213070&partnerID=8YFLogxK
UR - http://www.scopus.com/inward/citedby.url?scp=85091213070&partnerID=8YFLogxK
U2 - 10.1016/j.cgh.2019.07.060
DO - 10.1016/j.cgh.2019.07.060
M3 - Review article
C2 - 31401364
AN - SCOPUS:85091213070
SN - 1542-3565
VL - 18
SP - 2650
EP - 2666
JO - Clinical Gastroenterology and Hepatology
JF - Clinical Gastroenterology and Hepatology
IS - 12
ER -